Thornton, Karen
Thornton, Karen was paid $13.49M by Medicaid between Apr 2020 and Nov 2024, across 18 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 60% of everything it billed.
NEW YORK, NY 10019
Next to other Family Medicine Physician providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,750 | $50K | |
| 2021 | 4,141 | $131K | |
| 2022 | 86,288 | $1.36M | |
| 2023 | 390,931 | $11.92M | |
| 2024incomplete | 1,348 | $32K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 60% | 140,141 | 38,081 | $8.09M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 20% | 136,869 | 37,850 | $2.66M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.4% | 41,100 | 27,364 | $1.14M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.3% | 24,876 | 3,921 | $714K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.8% | 119,878 | 43,227 | $517K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 12,076 | 9,147 | $97K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 2,167 | 2,119 | $81K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,366 | 1,809 | $53K |
| S9083 | Global fee urgent care centers | <1% | 511 | 471 | $52K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 2,121 | 1,836 | $52K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 366 | 346 | $12K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 526 | 489 | $12K |
6 more codes
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 197 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 164 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 595 | $977.94 |
| 99243 | <1% | 45 | $746.04 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 31 | $302.42 |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 0% | 429 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.